



KINEXUS

Kinexus Bioinformatics Corporation Poised to Become a Global Leader in Proteomics and Bioinformatics

Kinexus Bioinformatics Corporation Launches Proteomic Analysis Service

FOR IMMEDIATE RELEASE NOVEMBER 14, 2000

VANCOUVER, British Columbia – Kinexus Bioinformatics Corporation, a Vancouver based proteomics and bioinformatics company announces the launch of its first Kinetworks Screening Services, powerful tests for mapping cell communication networks. Now Kinexus offers biomedical researchers in academia and the biopharmaceutical industry a significantly enhanced ability to simultaneously track the presence and activation states of hundreds of different kinase enzymes and their targets in cell and tissue specimens. Protein kinase enzymes have been linked to hundreds of human diseases including cancer, cardiovascular disease, diabetes, and neurological disorders.

“Kinetworks screens provide powerful tools for the discovery of new drug targets, new drugs, and the molecular diagnosis of disease: said Dr. Steven Pelech, President and CEO of Kinexus and a Professor at the University of British Columbia. “The introduction of these first two tests represents a significant milestone for Kinexus”. Kinexus’ institutional investors agree. A syndicate of investors, led by Milestone Medica Corporation and including BIRC Capital Corporation, Bio FutureFund Capital (VCC) Corporation and an angel investor have triggered the second tranche of an earlier \$1,165,000 financing on the strength of Kinexus’ performance. This second tranche raises the total financing to date to \$2.2 million.

The identification of validated drug targets and the rapid exclusion of inappropriate drug leads are two of the most critical bottlenecks in the drug discovery process today. Over \$50 billion is expended annually by the pharmaceutical industry, and approximately 40 per cent of this is directed towards early research and development activities. With the additional round of financing, the company is now well poised to exploit its unrivaled proprietary platform technology for tracking protein kinases and their targets. Kinexus will compile and analyze the data from the Kinetworks Screens to create bioinformatic databases, called Kininformatics databases, that will be available by website to subscribing customers. Kinexus is a dynamic Vancouver-based proteomics/bioinformatics firm that originated from research conducted at the University of British Columbia. The Company is dedicated to exploiting protein kinases for the molecular diagnosis of disease and drug discovery. Founder Dr. Steven Pelech said “Kinexus Bioinformatics Corporation represents his vision of creating a company that provides crucial sophisticated information to companies about potential drug targets, while at the same time advancing the field in a quantum way over other approaches.” Pelech and his management team of five professionals run operations at a 2,200 sq. ft. laboratory in the Don Rix company incubator building on UBC’s campus.

“We see an immediate source of revenue being generated from this unique technology,” said Dr. David Shindler, CEO of Milestone Medica. “Kinexus has a unique business model, strong management and proprietary technology that will expedite research in academia and biopharmaceutical companies around the world,” he added.

**For Further information, please contact Kinexus Bioinformatics Corporation toll free at
1-866-KINEXUS or visit our website at www.kinexus.ca**

PRESS RELEASE - 2000 NOVEMBER 14